SCHOLAR ROCK HOLDING CORPORATION Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 11.74 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.14M shares, a 39.34% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 21.67M shares, a 1.75% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 21.30M shares, a 4.78% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 20.32M shares, a 262.11% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 12.48M shares, a 39.52% decline from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 20.64M shares, a 6.48% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 19.38M shares, a 5.49% increase from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 18.37M shares, a 352.64% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 11.74M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 13.14M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 12.48M shares 10-K · filed 2026-03-03 | |||
| 2025-09-30 | 21.77M shares 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 21.94M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 21.67M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 20.64M shares 10-K · filed 2026-03-03 | |||
| 2024-09-30 | 22.21M shares 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | 21.31M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 21.30M shares 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 19.38M shares 10-K · filed 2025-02-27 | |||
| 2023-09-30 | 19.96M shares 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 20.34M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 20.32M shares 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | 18.37M shares 10-K · filed 2024-03-19 | |||
| 2022-09-30 | 18.31M shares 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 17.67M shares 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 5.61M shares 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 4.06M shares 10-K · filed 2023-03-07 | |||
| 2021-09-30 | 4.00M shares 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 4.60M shares 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | 4.56M shares 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | 3.74M shares 10-K · filed 2022-03-07 | |||
| 2020-09-30 | 4.23M shares 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 3.63M shares 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | 3.75M shares 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | 2.71M shares 10-K · filed 2021-03-09 | |||
| 2019-09-30 | 2.87M shares 10-Q · filed 2019-11-12 | 2.87M shares 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | 2.91M shares 10-Q · filed 2019-08-14 | 2.91M shares 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | 2.85M shares 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 2.30M shares 10-K · filed 2020-03-12 | |||
| 2018-09-30 | 2.37M shares 10-Q · filed 2019-11-12 | 2.37M shares 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | 2.49M shares 10-Q · filed 2019-08-14 | 2.49M shares 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | 16.89M shares 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | 16.34M shares 10-K · filed 2019-03-19 | |||
| 2017-09-30 | 12.84M shares 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | 12.48M shares 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |